List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4381222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Master protocol trial design for technical feasibility of MR-guided radiotherapy. Radiotherapy and Oncology, 2022, 166, 33-36.	0.6	1
2	Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2022, 167, 127-132.	0.6	20
3	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.6	7
4	Eye-specific quantitative dynamic contrast-enhanced MRI analysis for patients with intraocular masses. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 311-323.	2.0	7
5	Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. European Urology, 2022, 82, 252-257.	1.9	32
6	Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012. European Urology, 2022, , .	1.9	0
7	T1ϕfor Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 1998.	2.4	3
8	Integrated MRI-guided radiotherapy — opportunities and challenges. Nature Reviews Clinical Oncology, 2022, 19, 458-470.	27.6	47
9	"Who needs a mean dose if you can FLAME?― Radiotherapy and Oncology, 2022, , .	0.6	0
10	Machine learning-based analysis of CT radiomics model for prediction of colorectal metachronous liver metastases. Abdominal Radiology, 2021, 46, 249-256.	2.1	47
11	Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1211-1218.	6.4	23
12	Joint Registration and Segmentation via Multi-Task Learning for Adaptive Radiotherapy of Prostate Cancer. IEEE Access, 2021, 9, 95551-95568.	4.2	8
13	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.6	8
14	Characterization of Gas Electron Multiplierâ€based detector for external beam radiation therapy dosimetry. Medical Physics, 2021, 48, 1931-1940.	3.0	0
15	A multiâ€institutional analysis of a general pelvis continuous Hounsfield unit synthetic CT software for radiotherapy. Journal of Applied Clinical Medical Physics, 2021, 22, 207-215.	1.9	5
16	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 787-796.	1.6	267
17	Validation of a 4D-MRI guided liver stereotactic body radiation therapy strategy for implementation on the MR-linac. Physics in Medicine and Biology, 2021, 66, 105010.	3.0	12
18	68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability. Practical Radiation Oncology, 2021, 11, 202-211.	2.1	13

#	Article	IF	CITATIONS
19	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International Journal of Radiation Oncology Biology Physics, 2021, 111, 867-875.	0.8	37
20	Oropharyngeal primary tumor segmentation for radiotherapy planning on magnetic resonance imaging using deep learning. Physics and Imaging in Radiation Oncology, 2021, 19, 39-44.	2.9	30
21	The impact of image acquisition time on registration, delineation and image quality for magnetic resonance guided radiotherapy of prostate cancer patients. Physics and Imaging in Radiation Oncology, 2021, 19, 85-89.	2.9	4
22	Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. European Journal of Cancer, 2021, 153, 64-71.	2.8	21
23	Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study. Frontiers in Oncology, 2021, 11, 705964.	2.8	22
24	Anorectal dose–effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiotherapy and Oncology, 2021, 162, 98-104.	0.6	8
25	The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials. Radiotherapy and Oncology, 2021, 164, 202-208.	0.6	0
26	Reply to I. R. Vogelius et al. Journal of Clinical Oncology, 2021, 39, 3086-3087.	1.6	5
27	CT-Based Radiomics Analysis Before Thermal Ablation to Predict Local Tumor Progression for Colorectal Liver Metastases. CardioVascular and Interventional Radiology, 2021, 44, 913-920.	2.0	18
28	Probabilistic target definition and planning in patients with prostate cancer. Physics in Medicine and Biology, 2021, 66, 215011.	3.0	3
29	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. Cancers, 2021, 13, 5179.	3.7	7
30	Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 175-179.	0.6	15
31	Histopathological Features of MRIâ€Invisible Regions of Prostate Cancer Lesions. Journal of Magnetic Resonance Imaging, 2020, 51, 1235-1246.	3.4	24
32	ADC measurements on the Unity MR-linac – A recommendation on behalf of the Elekta Unity MR-linac consortium. Radiotherapy and Oncology, 2020, 153, 106-113.	0.6	60
33	Applicator visualization using ultrashort echo time MRI for high-dose-rate endorectal brachytherapy. Brachytherapy, 2020, 19, 618-623.	0.5	4
34	Tribute to David Thwaites. Radiotherapy and Oncology, 2020, 153, 5-6.	0.6	0
35	Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer. Radiotherapy and Oncology, 2020, 153, 114-121.	0.6	15
36	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	2.8	81

#	Article	IF	CITATIONS
37	Clinical workflow for treating patients with a metallic hip prosthesis using magnetic resonance imaging-guided radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 85-90.	2.9	8
38	A Deep Learning-based correction to EPID dosimetry for attenuation and scatter in the Unity MR-Linac system. Physica Medica, 2020, 71, 124-131.	0.7	11
39	3D dosimetric verification of unity MR-linac treatments by portal dosimetry. Radiotherapy and Oncology, 2020, 146, 161-166.	0.6	8
40	Technologyâ€driven research for radiotherapy innovation. Molecular Oncology, 2020, 14, 1500-1513.	4.6	60
41	Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1055-1062.	0.8	14
42	Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiation Oncology, 2020, 15, 41.	2.7	3
43	Quantitative imaging for radiotherapy purposes. Radiotherapy and Oncology, 2020, 146, 66-75.	0.6	71
44	Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiotherapy and Oncology, 2020, 147, 92-98.	0.6	109
45	Quantitative Magnetic Resonance Imaging for Biological Image-Guided Adaptive Radiotherapy. Frontiers in Oncology, 2020, 10, 615643.	2.8	37
46	Locally advanced rectal cancer: 3D diffusion-prepared stimulated-echo turbo spin-echo versus 2D diffusion-weighted echo-planar imaging. European Radiology Experimental, 2020, 4, 9.	3.4	2
47	Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5â€⊤ magnetic resonance imaging guided linear accelerator. Physics and Imaging in Radiation Oncology, 2019, 11, 16-20.	2.9	10
48	Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. Radiotherapy and Oncology, 2019, 140, 131-142.	0.6	24
49	The transformation of radiation oncology using real-time magnetic resonance guidance: A review. European Journal of Cancer, 2019, 122, 42-52.	2.8	136
50	Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy. Physics and Imaging in Radiation Oncology, 2019, 11, 61-62.	2.9	3
51	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.6	62
52	Multiparametric MRI Tumor Probability Model for the Detection of Locally Recurrent Prostate Cancer After Radiation Therapy: Pathologic Validation and Comparison With Manual Tumor Delineations. International Journal of Radiation Oncology Biology Physics, 2019, 105, 140-148.	0.8	7
53	Feasibility of Gold Fiducial Markers as a Surrogate for Gross Tumor Volume Position in Image-Guided Radiation Therapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1151-1159.	0.8	2
54	MRI commissioning of 1.5T MR-linac systems – a multi-institutional study. Radiotherapy and Oncology, 2019, 132, 114-120.	0.6	111

#	Article	IF	CITATIONS
55	Feasibility and accuracy of quantitative imaging on a 1.5 T MR-linear accelerator. Radiotherapy and Oncology, 2019, 133, 156-162.	0.6	80
56	Improved repeatability of dynamic contrastâ€enhanced MRI using the complex MRI signal to derive arterial input functions: a testâ€retest study in prostate cancer patients. Magnetic Resonance in Medicine, 2019, 81, 3358-3369.	3.0	10
57	MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer. Radiotherapy and Oncology, 2019, 132, 93-99.	0.6	15
58	Correcting geometric image distortions in sliceâ€based 4Dâ€MRI on the MRâ€linac. Medical Physics, 2019, 46, 3044-3054.	3.0	17
59	Twoâ€dimensional EPID dosimetry for an MRâ€linac: Proof of concept. Medical Physics, 2019, 46, 4193-4203.	3.0	12
60	MRI basics for radiation oncologists. Clinical and Translational Radiation Oncology, 2019, 18, 74-79.	1.7	17
61	Geometrical and dosimetric evaluation of breast target volume auto-contouring. Physics and Imaging in Radiation Oncology, 2019, 12, 38-43.	2.9	12
62	Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost. Frontiers in Oncology, 2019, 9, 1264.	2.8	16
63	Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after externalâ€beam radiation therapy. Journal of Magnetic Resonance Imaging, 2019, 50, 269-278.	3.4	22
64	Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy. European Radiology, 2019, 29, 4160-4168.	4.5	10
65	Tumor Trailing for Liver SBRT on the MR-Linac. International Journal of Radiation Oncology Biology Physics, 2019, 103, 468-478.	0.8	55
66	Pseudo-CT image generation from mDixon MRI images using fully convolutional neural networks. , 2019, , .		3
67	Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial. Radiotherapy and Oncology, 2018, 127, 74-80.	0.6	101
68	Monitoring early changes in rectal tumor morphology and volume during 5†weeks of preoperative chemoradiotherapy – An evaluation with sequential MRIs. Radiotherapy and Oncology, 2018, 126, 431-436.	0.6	6
69	Role of Prostate MR Imaging in Radiation Oncology. Radiologic Clinics of North America, 2018, 56, 319-325.	1.8	15
70	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clinical and Translational Radiation Oncology, 2018, 9, 48-60.	1.7	415
71	Benefit of adaptive CT-based treatment planning in high-dose-rate endorectal brachytherapy for rectal cancer. Brachytherapy, 2018, 17, 78-85.	0.5	3
72	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer―for Prostate Treatment?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 361-373.	0.8	132

UULKE A VAN DER HEIDE

#	Article	IF	CITATIONS
73	Performance of a fast and highâ€resolution multiâ€echo spinâ€echo sequence for prostate T ₂ mapping across multiple systems. Magnetic Resonance in Medicine, 2018, 79, 1586-1594.	3.0	24
74	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	2.9	8
75	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology, 2018, 13, 19-23.	1.7	41
76	Quantitative Imaging for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 683-686.	0.8	13
77	Retrospective self-sorted 4D-MRI for the liver. Radiotherapy and Oncology, 2018, 127, 474-480.	0.6	25
78	Imaging predictors of treatment outcomes in rectal cancer: An overview. Critical Reviews in Oncology/Hematology, 2018, 129, 153-162.	4.4	17
79	A Self-Sorting Coronal 4D-MRI Method for Daily Image Guidance of Liver Lesions on an MR-LINAC. International Journal of Radiation Oncology Biology Physics, 2018, 102, 875-884.	0.8	37
80	Impact of contrast agent injection duration on dynamic contrastâ€enhanced MRI quantification in prostate cancer. NMR in Biomedicine, 2018, 31, e3946.	2.8	4
81	Contouring of prostate tumors on multiparametric MRI: Evaluation of clinical delineations in a multicenter radiotherapy trial. Radiotherapy and Oncology, 2018, 128, 321-326.	0.6	36
82	Biochemical recurrence prediction after radiotherapy for prostate cancer with T2w magnetic resonance imaging radiomic features. Physics and Imaging in Radiation Oncology, 2018, 7, 9-15.	2.9	32
83	Significant tumor shift in patients treated with stereotactic radiosurgery for brain metastasis. Clinical and Translational Radiation Oncology, 2017, 2, 23-28.	1.7	16
84	Towards intrinsic R2* imaging in the prostate at 3 and 7 tesla. Magnetic Resonance Imaging, 2017, 42, 16-21.	1.8	8
85	Repeatability of dose painting by numbers treatment planning in prostate cancer radiotherapy based on multiparametric magnetic resonance imaging. Physics in Medicine and Biology, 2017, 62, 5575-5588.	3.0	21
86	Prostate fiducial marker detection with the use of multi-parametric magnetic resonance imaging. Physics and Imaging in Radiation Oncology, 2017, 1, 14-20.	2.9	23
87	Multicenter validation of prostate tumor localization using multiparametric <scp>MRI</scp> and prior knowledge. Medical Physics, 2017, 44, 949-961.	3.0	23
88	Diffusion-weighted-preparation (D-prep) MRI as a future extension of SPECT/CT based surgical planning for sentinel node procedures in the head and neck area?. Oral Oncology, 2016, 60, 48-54.	1.5	11
89	Consensus opinion on MRI simulation for external beam radiation treatment planning. Radiotherapy and Oncology, 2016, 121, 187-192.	0.6	66
90	An MRI-based mid-ventilation approach for radiotherapy of the liver. Radiotherapy and Oncology, 2016, 121, 276-280.	0.6	18

#	Article	IF	CITATIONS
91	Accuracy of PET/MRI coregistration of cervical lesions. Nuclear Medicine Communications, 2016, 37, 997-998.	1.1	0
92	The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. Urology Case Reports, 2016, 7, 67-69.	0.3	2
93	Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. International Journal of Radiation Oncology Biology Physics, 2016, 95, 680-689.	0.8	79
94	A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. Radiotherapy and Oncology, 2016, 119, 111-116.	0.6	26
95	Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland. Radiotherapy and Oncology, 2016, 119, 97-103.	0.6	12
96	Magnetic resonance imaging for prostate cancer radiotherapy. Physica Medica, 2016, 32, 446-451.	0.7	43
97	A 1.5 T transverse magnetic field in radiotherapy of rectal cancer: Impact on the dose distribution. Medical Physics, 2015, 42, 7182-7189.	3.0	23
98	Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation. Radiotherapy and Oncology, 2015, 115, 186-190.	0.6	102
99	Dose–surface maps identifying local dose–effects for acute gastrointestinal toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2015, 117, 515-520.	0.6	59
100	Impact of tumour invasion on seminal vesicles mobility in radiotherapy of prostate cancer. Radiotherapy and Oncology, 2015, 117, 283-287.	0.6	12
101	Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer. Acta Oncológica, 2015, 54, 839-846.	1.8	13
102	Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion. Radiotherapy and Oncology, 2015, 115, 96-100.	0.6	15
103	Acute Toxicity After Image-Guided Intensity Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 91, 737-744.	0.8	102
104	Re-distribution of brachytherapy dose using a differential dose prescription adapted to risk of local failure in low-risk prostate cancer patients. Radiotherapy and Oncology, 2015, 115, 308-313.	0.6	11
105	Reproducibility of the MRI-defined spinal cord position in stereotactic radiotherapy for spinal oligometastases. Radiotherapy and Oncology, 2014, 113, 230-234.	0.6	6
106	Accurate prostate tumour detection with multiparametric magnetic resonance imaging: Dependence on histological properties. Acta Oncológica, 2014, 53, 88-95.	1.8	39
107	Position shifts and volume changes of pelvic and para-aortic nodes during IMRT for patients with cervical cancer. Radiotherapy and Oncology, 2014, 111, 442-445.	0.6	24
108	Introduction: Magnetic Resonance Imaging Comes of Age in Radiation Oncology. Seminars in Radiation Oncology, 2014, 24, 149-150.	2.2	17

UULKE A VAN DER HEIDE

#	Article	IF	CITATIONS
109	Introduction: Systems for Magnetic Resonance Image Guided Radiation Therapy. Seminars in Radiation Oncology, 2014, 24, 192.	2.2	19
110	³¹ P MR spectroscopic imaging combined with ¹ H MR spectroscopic imaging in the human prostate using a double tuned endorectal coil at 7T. Magnetic Resonance in Medicine, 2014, 72, 1516-1521.	3.0	19
111	Free-form image registration regularized by a statistical shape model: application to organ segmentation in cervical MR. Computer Vision and Image Understanding, 2013, 117, 1119-1127.	4.7	26
112	Boosting imaging defined dominant prostatic tumors: A systematic review. Radiotherapy and Oncology, 2013, 107, 274-281.	0.6	115
113	Multiatlasâ€based segmentation with preregistration atlas selection. Medical Physics, 2013, 40, 091701.	3.0	54
114	FDG-PET and diffusion-weighted MRI in head-and-neck cancer patients: Implications for dose painting. Radiotherapy and Oncology, 2013, 106, 250-254.	0.6	51
115	Why prostate tumour delineation based on apparent diffusion coefficient is challenging: An exploration of the tissue microanatomy. Acta Oncológica, 2013, 52, 1629-1636.	1.8	22
116	Expression of hypoxia-inducible factor-1α and -2α in whole-mount prostate histology: Relation with dynamic contrast-enhanced MRI and Gleason score. Oncology Reports, 2013, 29, 2249-2254.	2.6	10
117	Tracer Kinetic Model Selection for Dynamic Contrast-Enhanced Computed Tomography Imaging of Prostate Cancer. Investigative Radiology, 2012, 47, 41-48.	6.2	19
118	Pathologic Validation of a Model Based on Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Tumor Delineation in the Prostate Peripheral Zone. International Journal of Radiation Oncology Biology Physics, 2012, 82, e537-e544.	0.8	68
119	A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 653-660.	0.8	22
120	The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy. Radiotherapy and Oncology, 2012, 103, 233-238.	0.6	17
121	Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging, 2012, 30, 1216-1223.	1.8	136
122	Segmentation of Cervical Images by Inter-subject Registration with a Statistical Organ Model. Lecture Notes in Computer Science, 2012, , 240-247.	1.3	1
123	Functional MRI for tumor delineation in prostate radiation therapy. Imaging in Medicine, 2011, 3, 219-231.	0.0	11
124	Internal motion of the vagina after hysterectomy for gynaecological cancer. Radiotherapy and Oncology, 2011, 98, 244-248.	0.6	29
125	Influence of Antiflatulent Dietary Advice on Intrafraction Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e401-e406.	0.8	26
126	Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 2011, 12, 255.	1.6	156

#	Article	IF	CITATIONS
127	Phaseâ€based arterial input function measurements in the femoral arteries for quantification of dynamic contrastâ€enhanced (DCE) MRI and comparison with DCEâ€CT. Magnetic Resonance in Medicine, 2011, 66, 1267-1274.	3.0	34
128	Quality Assurance of 4D-CT Scan Techniques in Multicenter Phase III Trial of Surgery Versus Stereotactic Radiotherapy (Radiosurgery or Surgery for Operable Early Stage (Stage 1A)) Tj ETQq0 0 0 rgBT /Ove	erlock 10 7 0.8	Tf 50,702 Td (1
	Physics, 2011, 80, 918-927.		
129	Focal Salvage Guided by T2-Weighted and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prostate Cancer Recurrences. International Journal of Radiation Oncology Biology Physics, 2010, 76, 741-746.	0.8	59
130	Label Fusion in Atlas-Based Segmentation Using a Selective and Iterative Method for Performance Level Estimation (SIMPLE). IEEE Transactions on Medical Imaging, 2010, 29, 2000-2008.	8.9	233
131	Dynamic Contrast-enhanced CT for Prostate Cancer: Relationship between Image Noise, Voxel Size, and Repeatability. Radiology, 2010, 256, 976-984.	7.3	27
132	The use of probability maps to deal with the uncertainties in prostate cancer delineation. Radiotherapy and Oncology, 2010, 94, 168-172.	0.6	19
133	Validation of functional imaging with pathology for tumor delineation in the prostate. Radiotherapy and Oncology, 2010, 94, 145-150.	0.6	97
134	Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiotherapy and Oncology, 2010, 95, 185-190.	0.6	219
135	Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiotherapy and Oncology, 2010, 96, 38-42.	0.6	70
136	Registration of Cervical MRI Using Multifeature Mutual Information. IEEE Transactions on Medical Imaging, 2009, 28, 1412-1421.	8.9	84
137	Simultaneous multi-modality ROI delineation in clinical practice. Computer Methods and Programs in Biomedicine, 2009, 96, 133-140.	4.7	91
138	Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncology, 2009, 4, 1.	2.7	226
139	Healthâ€related quality of life 3 years after highâ€dose intensityâ€modulated radiotherapy with gold fiducial markerâ€based position verification. BJU International, 2009, 103, 762-767.	2.5	31
140	Effect of Translational and Rotational Errors on Complex Dose Distributions With Off-Line and On-Line Position Verification. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1600-1608.	0.8	193
141	In Reply to Dr. Xiao et al International Journal of Radiation Oncology Biology Physics, 2009, 75, 318.	0.8	4
142	Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiotherapy and Oncology, 2009, 90, 291-298.	0.6	49
143	Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. Radiotherapy and Oncology, 2009, 93, 180-184.	0.6	17
144	Intrafraction motion in patients with cervical cancer: The benefit of soft tissue registration using MRI. Radiotherapy and Oncology, 2009, 93, 115-121.	0.6	44

UULKE A VAN DER HEIDE

#	Article	IF	CITATIONS
145	High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiation Oncology, 2008, 3, 15.	2.7	79
146	How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer. BJU International, 2008, 101, 944-947.	2.5	3
147	MRI/linac integration. Radiotherapy and Oncology, 2008, 86, 25-29.	0.6	444
148	Motion and deformation of the target volumes during IMRT for cervical cancer: What margins do we need?. Radiotherapy and Oncology, 2008, 88, 233-240.	0.6	141
149	Comparison of biologically equivalent dose–volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiotherapy and Oncology, 2008, 88, 46-52.	0.6	45
150	Online MRI guidance for healthy tissue sparing in patients with cervical cancer: An IMRT planning study. Radiotherapy and Oncology, 2008, 88, 241-249.	0.6	65
151	Automatic segmentation of the prostate in 3D MR images by atlas matching using localized mutual information. Medical Physics, 2008, 35, 1407-1417.	3.0	356
152	Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiotherapy and Oncology, 2007, 82, 38-45.	0.6	137
153	Intrafraction Motion of the Prostate During External-Beam Radiation Therapy: Analysis of 427 Patients with Implanted Fiducial Markers. International Journal of Radiation Oncology Biology Physics, 2007, 69, 419-425.	0.8	343
154	Health-Related Quality of Life in Patients With Locally Advanced Prostate Cancer After 76 Gy Intensity-Modulated Radiotherapy vs. 70 Gy Conformal Radiotherapy in a Prospective andÂLongitudinalÂStudy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 656-661.	0.8	66
155	Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. International Journal of Radiation Oncology Biology Physics, 2006, 64, 189-196.	0.8	182
156	Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multi-slice CT. Physics in Medicine and Biology, 2006, 51, 4329-4343.	3.0	20
157	An accurate calibration method of the multileaf collimator valid for conformal and intensity modulated radiation treatments. Physics in Medicine and Biology, 2004, 49, 2631-2643.	3.0	32
158	Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiotherapy and Oncology, 2003, 67, 295-302.	0.6	162
159	Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiotherapy and Oncology, 2003, 68, 81-88.	0.6	111
160	Orientation Changes of the Myosin Light Chain Domain During Filament Sliding in Active and Rigor Muscle. Journal of Molecular Biology, 2002, 318, 1275-1291.	4.2	69
161	Polarized Fluorescence Depletion Reports Orientation Distribution and Rotational Dynamics of Muscle Cross-Bridges. Biophysical Journal, 2002, 83, 1050-1073.	0.5	11
162	Measurements and clinical consequences of prostate motion during a radiotherapy fraction. International Journal of Radiation Oncology Biology Physics, 2002, 53, 206-214.	0.8	147

#	Article	IF	CITATIONS
163	Partial boosting of prostate tumours. Radiotherapy and Oncology, 2001, 61, 117-126.	0.6	30
164	Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients. Frontiers in Oncology, 0, 12, .	2.8	9